Capable of processing from small quantities to large quantities! A gene introduction device applicable from basic research to clinical use.
The "MaxCyte STX" is a cell transfection device from MaxCyte, Inc. that can process a large number of cells at once (capable of transfecting 100 million cells). MaxCyte's transfection technology is based on the general principle of electroporation, which enhances temporary membrane permeability by generating an electric field in a cell suspension to introduce external substances such as DNA into the cells. The "MaxCyte STX" utilizes this fundamental principle and is a patented electroporation system that is simple and flexible, allowing for processing from small to large scales. 【Features】 - Simplicity and flexibility of the system enabling processing from small to large scales - Stable transfection performance → High transfection efficiency and cell viability - Wide range of applications → From basic research to clinical applications For more details, please contact us or download the catalog.
Inquire About This Product
basic information
【Specifications】 [Gene Delivery Device] ○ Delivery Efficiency: Over 90% (When introducing a DNA plasmid coding for GFP into CHO cells) ○ Survival Rate: Over 90% (When introducing a DNA plasmid coding for GFP into CHO cells) ○ Processing Capacity: 5×10⁵ to 1×10¹⁰ cells ○ Processing Speed: Up to 1×10¹⁰ cells within 30 minutes ○ Delivery Method: Flow Electroporation Method ○ Main Unit Dimensions: W460×D540×H700mm ○ Power Capacity: AC100V 2A [Others] ○ Computer: Equivalent to HP Compaq dx2000MT ○ Software: MaxCyte STX Software ○ Uninterruptible Power Supply: Equivalent to APC BR1000G-JP ● For more details, please contact us or download the catalog.
Price information
Please contact us.
Delivery Time
※Please contact us.
Applications/Examples of results
【Application Scope】 ○ Cell preparation in ex vivo cell therapy ○ Prototype for research or evaluation tests of various proteins, including antibodies ○ Large-scale preparation of homogeneous gene introduction target cells used in drug discovery research ● For more details, please contact us or download the catalog.
catalog（1）
Download All Catalogs
Company information
BTB Japan Co., Ltd. is a company primarily engaged in introducing and mediating biotechnology originating from Europe and the United States. The feasibility studies for commercializing concepts arising from basic research were initially conducted as bridging research from basic research to clinical research in the field of drug development, and in recent years, their importance has been recognized not only in Europe and the United States but also in our country. It is clear that the smooth practical application of technological innovation cannot be achieved without collaboration among industry, government, and academia, given the multifaceted nature of bridging research, and this situation is no different in Japan, the U.S., and Europe. The significance of venture companies from Europe and the United States among the members of the "industry" involved in bridging research can be inferred from the fact that their annual establishment numbers are more than ten times that of Japan, and it is not uncommon for multiple venture companies to participate in development systems involving industry, government, and academia. Leveraging the extensive network we have cultivated through our experience, we aim to introduce, mediate, and facilitate new biotechnologies originating from these European and American venture companies to Japanese businesses. Additionally, through our network, we focus on introducing biotechnologies that possess comparative advantages in terms of innovation and product viability.